Clinipace Acquisition Pan-Asia CRO, Choice Pharma
Choice Pharma provides Clinipace a significant Pan-Asia footprint
Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements
There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.
This is the 5th acquisition by Clinipace in recent years.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
